Canadian Cancer Trials Group Bulletins

General


Recent Publication

Archival tumour samples were collected from 94 women with recurrent or metastatic endometrial cancer who participated in 3 Canadian Cancer Trials Group phase II trials investigating single-agent mTOR inhibitors -- IND.160A and IND.160B (temsirolimus) and IND.192 (ridaforolimus). The aim of this study was to identify molecular markers associated with mTOR inhibitor activity in women with metastatic endometrial cancer.

The investigators reported that no predictive biomarker or combination of biomarkers for mTOR inhibitor activity were identified in this study. Restriction and enrichment of study entry, especially based on archival tumour tissue, should be undertaken with caution in trials using these agents.

Mackay HJ, Eisenhauer EA, Kamel-Reid S, Tsao M, Clarke B, Karakasis K, Werner HMJ, Trovik J, Akslen LA, Salvesen HB, Tu D, Oza AM. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer (ONLINE). Cancer n/a, 2013.

http://dx.doi.org/10.1002/cncr.28414